Predictive markers of atrial fibrillation in patients after acute ST-elevated myocardial infarction (the results of observational program “FAKEL”)

Aim. To assess probability of atrial fibrillation (AF) in patients after ST-elevated myocardial infarction (STEMI) with undergone primary percutaneous coronary intervention (PCI).

Material and methods. Prospective study in the period from December 2015 to November 2017 was carried out with consecutive inclusion of 107 patients at outpatient follow-up stage after STEMI who have undergone primary PCI. The mean age of patients was 69,5+7,8 years (40 (37,4%) women). Follow-up period was 18 months and included three visits (V): V₁ — when included in the study, V₂ — after 12 months, and V₃ — after 18 months. The endpoints of the study were cases of first diagnosed AF, cardioembolic stroke and death. At all visits predictive markers (Willebrand factor, Cystatin C, N-terminal prohormone of brain natriuretic peptide (NT-proBNP), galectin-3) in the blood plasma were determined.

Results. After 18 months of follow-up period in 19 (17,8%) patients were diagnosed AF, 5 of them (4,7%) had cardioembolic stroke, and 3 patients died. Median time of AF development from the onset of STEMI was 308 days. Cox multivariate analysis showed that the risk factors for first diagnosed AF were NT-proBNP — relative risk (RR): 1,05; 95% confidence interval (CI): 0,99-1,10 (p=0,038), cystatin C — RR: 1,44; 95% CI: 0,98-2,12 (p=0,043), galectin-3 — RR: 1,20; 95% CI: 1,03-1,40 (p=0,022).

Conclusion. There was a highly significant relationship between NT-proBNP of ≥400,0 pg/mL, cystatin С of ≥1,45 ng/mL and galectin-3 of ≥25 mg/mL in patients after STEMI who underwent primary PCI. These markers might serve as predictors of first diagnosed AF. Identification of these biomarkers may have potential therapeutic benefit in improving the prognosis of patients after STEMI who have undergone primary PCI and reduce mortality from cardioembolic stroke.

1. Forouzanfar MH, Alexander L, Anderson HR, et al. Global, regional, and national comparative risk assessment of 79 behavioral, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386:2287-323. https://doi.org/10.1016/S0140-6736(15)00128-2.

2. Wang J, Tan GJ, Han LN, et al. Novel biomarkers for cardiovascular risk prediction. Geriatr Cardiol. 2017;14(2):135-50. https://doi.org/10.11909/j.issn.1671-5411.2017.02.008.

3. Gallagher AM, van Staa TP, Murray-Thomas T, et al. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. BMJ Open. 2014;4(1):003839. https://doi.org/10.1136/bmjopen-2013-003839.

4. Angeli F, Reboldi G, Garofoli M, et al. Atrial fibrillation and mortality in patients with acute myocardial infarction: a systematic overview and meta-analysis. Curr Cardiol Rep. 2012;14(5):601-10. https://doi.org/10.1007/s11886-012-0289-3.

5. Wong CK, White HD, Wilcox RG, et al. Significance of atrial fibrillation during acute myocardial infarction, and its current management: insights from the GUSTO-3 trial. Card Electrophysiol Rev. 2003;7:201-7. https://doi.org/10.1007/s11886-012-0289-3.

6. St John Sutton M. Quest for diastolic prognostic indicators of clinical outcome after acute myocardial infarction. Circulation. 2008; 117(20):2570-2. https://doi.org/10.1161/CIRCULATIONAHA.108.772483.

7. Guo Y, Lip GY, Apostolakis S. Inflammation in atrial fibrillation. JACC. 2012;60(22):2263-70.

8. . Smith JG, Newton-Cheh C, Almgren P, et al. Assessment of conventional cardiovascular risk factors and multiple biomarkers for the prediction of incident heart failure and atrial fibrillation. JACC. 2010;56(21): 1712-9. https://doi.org/10.1016/j.jacc.2010.05.049.

9. Lee SH, Park SA, Ko SH, et al. Insulin resistance and inflammation may have an additional role in the link between cystatin C and cardiovascular disease in type 2 diabetes mellitus patients. Metabolism. 2010;59(2):241-6. https://doi.org/10.1016/j.metabol.2009.07.019.

10. Liu P, Sui S, Xu D, et al. Clinical analysis of the relationship between cystatin C and metabolic syndrome in the elderly. Russ J Rev Port Cardiol. 2014;33(7-8):411-6.

11. Yap YG. Inflammation and atrial fibrillation: cause or para-phenomenon? Europace. 2009;11(8):980-1. https://doi.org/10.1093/europace/eup191.

12. Radwan H, Selem A, Ghazal K. Value of N-terminal pro brain natriuretic peptide 16. in predicting prognosis and severity of coronary artery disease in acute coronary syndrome. J Saudi Heart Assoc. 2014;26(4):192-8. https://doi.org/10.1016/j.jsha.2014.04.004.

13. Garcia-Alvarez A, Sitges M, Delgado V, et al. Relation of plasma brain natriuretic peptide levels on admission for ST-elevation myocardial infarction to left ventricular end-diastolic volume six months later measured by both echocardiography and cardiac magnetic resonance. Am J Cardiol. 2009;104(7):878-82. https://doi.org/10.1016/j.amjcard.2009.05.025.

14. Lok DJ, Van Der Meer P, de la Porte PW, et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol. 2010 May;99(5):323-8. https://doi.org/10.1007/s00392-010-0125-y.

15. Shulman VA, Shesternya PA, Golovenkin SE, et al. Prognostic value of atrial fibrillation with regard to early and late outcomes of myocardial infarction Journal of Arrhythmology. 2005;39:5-9. (In Russ.)

16. Jons C, Jacobsen UG, Joergensen RM, et al. Cardiac Arrhythmias and Risk Stratification after Acute Myocardial Infarction (CARISMA) Study Group. The incidence and prognostic significance of new-onset atrial fibrillation in patients with acute myocardial infarction and left ventricular systolic dysfunction: a CARISMA substudy. Heart Rhythm. 2011;8(3):342-8. https://doi.org/10.1016/j.hrthm.2010.09.090.